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Drug discoveryCancer research over the past decades has revealed a number of molecular, biochemical, and cellular events that
reﬂect progressive transformation of normal human cells into theirmalignant derivatives. These ﬁndings help to
better understand the complexity of human tumorigenesis. In our study, molecular information is organized to
chart a comprehensive map of the signaling network for human cancer. It includes transcriptional and transla-
tional regulation and diverse feedback-control loops. It is demonstrated that applying this signaling network
map allows predicting the effect of targeted therapy before it can be applied into practice to reduce clinical
trial risks. Hence, the proposed map with prognosticating potential effect might become part of drug discovery
programs for targeted therapy. Applied in individual patient care it helps to reduce the current reliance of cancer
treatment on chemotherapies with low therapeutic indices. This study also demonstrates that continuing eluci-
dation of tumorigenesis will not only need heterotypic organ culture systems in vitro and increasingly reﬁned an-
imal models in vivo, but also computationally calculable virtual cell models in silico.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The fundamental trait of living cells is to sense and respond to inter-
nal as well as external stimuli and perturbations in order to carefully
control a homeostasis within a cell and maintain the function and
architecture of the cellular system [1]. These abilities are mainly linked
to the “signaling network”, which functions as an interface between
the environment, the genome and the metabolism [2]. Over the past
decades, cancer research developed the knowledge of human tumori-
genesis based on the fundamental ability of cancer cells for sustaining
chronic proliferation and twisting mitogenic signaling within the cellu-
lar system [3–6]. Elucidating the deregulated signaling events responsi-
ble for neoplastic transformation led to rationally designed targeted
therapies, which resulted in launching a large number of drug discovery
programs. The central issue of drug discovery programs is to identify the
key molecular target in the right pathway. Unfortunately, as drug
discovery programs advance, many types of preclinical cancer models
in vitro and in vivo fail to provide reliable prediction and veriﬁcation
[7,8]. In order to address this challenge, a comprehensive molecular
signaling map of a human cell is constructed, which includes different
signaling pathways associated with diverse transcriptional, translation
regulations and feedback-control mechanisms. During this study, this
molecular signalingmap has been applied for predicting drug responses
of different types of cancer cell lines and the results are promising.ics, Biometry andEpidemiology,
.
. This is an open access article under2. Results
2.1. The construction of the molecular signaling map (MSM)
The complex MSM is constructed by a curated activity considering
different levels of deﬁnitions and is made available. The level of node
deﬁnition includes component creation representing gene, RNA, protein,
compound and others. Within the MSM, each node (biological compo-
nent) is uniquely labeled using Ensembl-Id (gene, RNA), UniProt-Id
(protein), ChEBI-Id (compound) and MSM-Id (complex, pseudo-
object). Subsequently, the deﬁnition of edge between nodes represents
corresponding biochemical reactions. For instance, an edge representing
a transcription reaction is deﬁned by linking a node of gene to a mRNA
node. An edge representing a phosphorylation reaction is deﬁned as a
link between a protein node and a further protein node representing
the phosphorylation-modiﬁcation (Fig. 1A). The MSM also contains pos-
itive and negative feedback loops (Fig. 1B; Supplementary information
1). They ensure a homeostatic regulation of signal-transduction such as
signal ampliﬁcation and signal desensitization [9].
Finally, signaling pathways (EGF-, mTor-, Notch-, BMP-signaling)
are deﬁned (Fig. 1C; Supplementary information 2). Each pathway
generally contains three stages: signal initialization, signal ampliﬁca-
tion, and signal transduction. For the EGF-signaling pathway, signal
initialization contains biochemical reactions including the creation of
an EGF ligand through corresponding transcription and translation;
the speciﬁcal binding of an EGF ligand with its cellular receptor
(EGFR), which promotes the dimerization of a ligand receptor complex.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. (A) Node and edge deﬁnition in the MSM. A node in the MSM presents a basic component of the cellular system. An edge in the MSM presents a biochemical reaction which can
happen in the cellular system. There are 5 different types of edges shown here: (1) transcription; (2) translation; (3) miRNA regulation; (4) phosphorylation; and (5) degradation.
Therefore, the deﬁnition of edge means not only the linkage of different nodes to form a molecular network, but also contains the underlying biological meaning. (B) The feedback
loop in the MSM. A feedback loop is an important part of a signaling network. Because of its feedback control function, the dynamics could be bestowed on a signaling network. Here
is a simpliﬁed negative feedback loop visualized. This loop presents crosstalk between three different signaling pathways: JAK-STAT-, Insulin- andMAPK-signaling (Supplementary infor-
mation 1 shows all possible feedback loops within theMSM). (C) The deﬁnition of a signaling pathway inMSM. TheMSM contains 51 signaling pathways. Here is the simpliﬁedWnt sig-
nalingpathway visualized,which is focused on the protein and complex level. For the sake of simplicity, all genes, RNAs and their related transcriptions, translations andmiRNA regulations
in this signaling pathway are not shown here. (D) Modeling the drug inhibition effect. The kinetics of drug–target binding reaction is deﬁned by applying the mass action law. The con-
centration of the drug and target complex is dependent on the concentration of the drug and target and the corresponding dissociation constant.
2835J. Li, U.R. Mansmann / Cellular Signalling 26 (2014) 2834–2842Signal ampliﬁcation includes adapter protein (Grb2, Sos) recruitment
by an activated dimerized EGF ligand receptor complex, which subse-
quently leads invoking the activation of MAPK signaling. Signal trans-
duction starts from the activation of different downstream targets(such as AXL1, FOS, CREB, ATF, TP53, CEBPA) and ends with the
transactivation of diverse target-genes [10]. The transcriptional regula-
tion of microRNA (miR) is integrated into the MSM using information
from the TransmiR database (version 1.2) [11], which provides detailed
Table 1
Statistical summary of components and reactions in the MSM. The
complex includes a protein–protein complex, a protein–metabolite
complex, a protein–mRNA complex and a protein–gene complex.
The compound is a metabolite. PseudoObj includes protein-
inhibitors (EGFR inhibitor, Abl inhibitor and other) and hallmarks
(tumorigenesis, proliferation, apoptosis, etc.).
Component No. Reaction No.
Gene 1326 Transcription 1326
mRNA 2652 Translation 1680
Protein 1680 Decay 6457
miRNA 1048 Complex-formation 1002
Compound 49 Translocation 2825
Complex 1002 Phosphorylation 1243
Pseudo-object 75 Dephosphorylation 1243
Activation 254
miRNA-binding 5393
Sum 7832 Sum 21,423
2836 J. Li, U.R. Mansmann / Cellular Signalling 26 (2014) 2834–2842information regarding the type and effect of transcriptional regulations
on miRs, as well as corresponding literature information. The relation-
ship between miRs and their targets is deﬁned in the MSM and is
based on the information from the mirWalk database [12]. Table 1
summarizes the statistics of components and reactions. Fig. 2 shows a
simpliﬁed network overview of this curated molecular signaling map.2.2. Integration of cancer hallmarks
In 2013, the study of Li &Mansmann [13] explained that four cancer
hallmarks had been integrated into a COX-based signaling network
(sustained angiogenesis, tissue invasion, proliferation and evading
apoptosis proposed by Hanahan and Weinberg [14]). Similarly, these
four cancer hallmarks are deﬁned in theMSM. Additionally,ﬁve another
cancer hallmarks (insensitivity-to-anti-growth-signals, limitless-
replicative-potential, drug-resistance, cell-cycle-progression, and
apoptosis) were integrated into MSM. These nine cancer hallmarks in
the MSM reﬂect different novel capabilities which are acquired during
human tumorigenesis. Each of them symbolizes a successful security-
breaching of a corresponding anti-neoplastic defense-mechanism
within the cellular system of normal tissues [14]. Fig. 3 visualizes the re-
lationship between signaling pathways and cancer hallmarks in the
MSM.
The quantitative value of the hallmark insensitivity-to-anti-grow-
signals is deﬁned as the ratio of the sum of inoperative SMADs over
the sum of operative SMADs [15,16]. Inoperative SMADs have lost orig-
inal cellular functions by, for example, being bound to UBB for degrada-
tion, or being bound to I-SMAD. This links the hallmark to the TGF-beta-,
BMP-, Activin- and Met-receptor-signaling pathway. The quantitative
value of the hallmark limitless-replicative-potential is the amount of
TERT protein, which is involved in the cell-cycle pathway [17,18]. The
quantitative value of the hallmark drug resistance is the ratio of the
sum of different cellular transporter proteins such as ABCB, ABCC, and
ABCG over the amount of tumor suppressor protein XAF1,whose down-
regulation confers drug resistance for most cancer cells [19,20]. This
links the hallmark to the ABL- and BRCA-signaling pathways. The quan-
titative value of the hallmark cell-cycle progression is the ratio of the sum
of cell-cycle promoters such as different complexes of cyclin proteins
and their corresponding cyclin-dependent kinases over the sum of dif-
ferent cyclin-dependent kinase inhibitors such as p15, p16, p18, and
p19 [21,22]. Therefore, the hallmark cell-cycle progression is implicated
in the cell-cycle-, BRCA-, and PI3K-signaling pathway. The quantitative
value of the hallmark apoptosis is the ratio of the sum of pro-apoptotic
proteins such as BAX, BID, and BAK, over the sum of anti-apoptotic
proteins such as Bcl-Xl and Bcl-2 [23,24]. This hallmark is linked to the
TP53-, ATM- and PAK-signaling pathway. The quantitative value of the
hallmark self-sufﬁciency-in-growth-signals is deﬁned as the sum of
different gain-of-function mutational key protein kinases from theMAPK signaling pathway that can confer the constitutive active activity
to this pathway, therefore enabling the capacity for becoming indepen-
dent in growth signals. Table 2 summarizes the implementation of the
cancer hallmark in the MSM and related literature information.
2.3. Drug response prediction of NCI-60 cancer cell lines
A systematic use of genomic cancer data to predict therapeutic
responses of individual cancer cell lines is of great importance for
preclinical research. Thus, genomic data including gene expression
data and miRNA expression data of the NCI-60 cancer panel (60 cell
lines) were incorporated into MSM. After initialization of the MSM
with the genomic data, Petri net simulation generates a signal ﬂux in
the MSN. A total of 60 different control steady-states with stable signal
ﬂuxes of these corresponding 60 cancer cell lines were created (Supple-
mentary information 3). Furthermore, molecular inhibitions of ten sig-
naling agents (dasatinib, erlotinib, lapatinib, geﬁtinib, everolimus,
imatinib, nilotinib, sorafenib, sunitinib, and temsirolimus) were
modeled into theMSM (Table 3;Materials andmethods) and 600 inter-
ventional perturbation states of changed signal ﬂuxes were generated.
The Flux-Comparative-Analysis (FCA) was applied to calculate the ra-
tios of the impact of signal-ﬂux changes between each perturbation
state and its corresponding control state and quantify the impact on
the hallmark proliferation. The FCA assesses whether a molecular per-
turbation can invoke a signiﬁcant ﬂux change regarding selected
model components [13]. In this case, the goal is to investigate whether
a certain type of drug inhibition could reduce the proliferation ability
of the underlying cellular system. The MSM based ﬂux-change ratio of
the hallmark proliferation were compared with experimentally mea-
sured sensitivity-scores from the study of Holbeck et al. [25]. Table 4
and Supplementary information 4 show the sensitivity and speciﬁcity
of MSM based drug-response prediction with 95% conﬁdence-interval.
Among these ten signaling agents, the responses of sorafenib,
temsirolimus and everolimus are predicted with best sensitivities:
97.3% (95% CI [85.8; 99.3]), 88.5% (95% CI [76.6; 95.6]) and 88.0% (95%
CI [75.7; 95.5]) respectively (Table 4; Fig. 4A, B and C). In MSM, the
sorafenib is implemented to reduce the function of the proteins FLT3,
FLT4, and KIT (Table 3), which results in the signal-ﬂux inhibition of
signaling pathways including the KIT-, PDGF-, JAK-STAT-, and
ErbB-pathway in the MSM. The temsirolimus and everolimus are both
implemented as the MTOR inhibitor. They directly inhibit the MTOR
pathway, which can crosstalk to the AMPK-, AKT-, Insulin-, HIF-1-, TGF-
beta-, Death-receptor-, and Wnt-pathway in MSM [26–28]. Compared
to everolimus, temsirolimus can additionally inhibit the VEGF receptors
and therefore can exert angiogenesis-inhibition (Table 3). However, the
speciﬁcities of the predicted drug responses of these three signaling
agents are low (Table 4; Supplementary information 4).
Erlotinib, geﬁtinib and lapatinib are three selective tyrosine kinase-
inhibitors and mainly target the EGFR. The sensitivities of their predict-
ed responses are low: 43.8% (95% CI [23.2; 65.5]), 45.8% (95% CI [25.6;
67.2]) and 56.5% (95% CI [34.5; 76.8]). However, the speciﬁcities of
their prediction responses are high: 86.8% (95% CI [71.9; 95.6]), 89.2%
(95% CI [74.6; 97.0]) and 81.5% (95% CI [65.7; 92.3]). Speciﬁc differences
between these three types of inhibitions are modeled in the MSM:
erlotinib additionally inhibits proteins ERBB4, LYN and SRC (Table 3).
The ERBB4 is a member of the EGFR family and can therefore bind to
different ligands to invoke a downstream signal cascade [29]. LYN and
SRC are proto-oncogenes and important members of the Src-family. In
the MSM, they regulate diverse signaling cascades including the
Erythropoietin-, Jak-Stat-, MAPK-, PDGFR-, KIT-, and Prolactin-signaling
pathway [30]. Furthermore, in the MSM, the expression level of
members of the Src-family are correlated with expression levels of
microRNAs including miR-126, -143, -145, -218 and -224 [31,32].
Geﬁtinib additionally targets the ERBB2, ERBB4 and LYN. The dissociation
rate between geﬁtinib and its target ERBB2 is at the high level of
3500 nM. Similarly, lapatinib additionally targets only the ERBB2 and
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Fig. 3. Relationship between cancer hallmarks and signaling pathways. The graph visualizes only this relationship; therefore, links between signaling pathways and cancer hallmarks are
different than edges deﬁned in MSM. A link here only means that it exists components in corresponding signaling pathways that can have an impact on the perspective of cancer
development, which the linked cancer hallmark represents.
2838 J. Li, U.R. Mansmann / Cellular Signalling 26 (2014) 2834–2842ERBB4 with dissociation rates of 7 and 54 nM, which are low in compar-
ison with erlotinib and geﬁtinib.
Interestingly, among the chosen ten signaling agents, the imatinib
has the lowest sensitivity: 10.0% (95% CI [0.25; 44.5]) and the highest
speciﬁcity: 98.0% (95% CI [89.5; 99.9]) (Fig. 4D). In MSM, this signalingTable 2
Cancer hallmark implementation. P-PAK2_P34 symbolizes that the PAK2 protein is phospho
mut-BRAF signiﬁes the mutant version of BRAF (in this case, the gain-of-function). The referen
Hallmark Implementation
Apoptosis (A) A = Active-CASP3 ∗ (AIFM + ENDOG + TP53 + TP63 +
Cell-cycle-progression (CC) CC = (P-CDKN1B + P-CDKN1A + CCND1:CDK4_6 + CCD
CCNE:CDK2_3 + Active-CCNB:CDK1) / (1 + INK_ACD +
Active-CHEK1 + BRCA1:BARD1)
Drug-resistance (D) D = P-RAD51_T315 / (1 + XAF1)
Evading-apoptosis (EA) EA = (TNF1:TNFRSF1B + P-IGF1R:IGF1 + P-IGF1R:IGF2 +
(1 + FAS:FASLG + TNFSF10:DR4_5 + TNF1:TNFRSF1A +
Insensitivity-to-anti-growth-
signals (IS)
IS = (SMAD2_3:UBB + SMAD1_5_8:UBB + I_SMAD:SM
P-SMAD1_5_8:SMAD4)
Limitless-replicative-
potential (LP)
LP = TERT
Proliferation (P) P = P-EIF4EBP1 + P-MYC:MAX + URGCP + MKI67 +
TOP2A + STK6 + PLK1 + FOXM1 + PCNA
Self-sufﬁciency-in-growth-
signals (SS)
SS = mut-BRAF + BRAF:mut-KRAS + BRAF:mut-HRAS
mut-EGFR + mut-ERBB2
Sustained-angiogenesis (SA) SA = (P-FGFR:FGF + P–KDR_dimer:VEGFC + P–KDR_dim
IL8 + GM-CSF + TIMP) / (1 + CD36:THBS1)
Tissue-invasion (TI) TI = MMP7 + MMP9 + MMP2 + MMP1 + MMP13 +agent is implemented to inhibit the function of the proteins ABL1/2,
KIT, and PDGFR (Table 3). According to FCA analysis, in some NCI-60
cell lines such as EKVX, TK-10, and U251, the signal ﬂuxes from the
BDNF-, Met-receptor-, VEGF-, and Activin-signaling pathways were
increased after imatinib treatment. Furthermore, the expression levelsrylated at the 34th site. CDK4_6 indicates an object-entity containing CDK4 and CDK6.
ce ID is PubMed ID.
Reference (PubMed)
TP73 + P-PAK2_P34 + HIPK2) 10200555, 16239930, 17626635, 21248071,
18767140, 20193641
N2:CDK4_6 + CCDN3:CDK4_6 +
CDKN2B + BRCA2:RAD51 +
21045237, 19106607, 18406353, 16522651,
8840967, 20202217, 15665856, 19238148
11087668, 2085543, 21807066, 17329253
BCL2L1 + BCL2 + MCL1) /
BAX + BAK1 + PMAIP1 + BBC3)
14634624, 17846171, 21608150, 20182539,
8524870
AD4) / (1 + P-SMAD2_3:SMAD4 + 19114990, 14534577, 22710166
16869755, 21792193, 22396899
TRIM21 + MYBL2 + 15184677, 10430922, 12454650, 12620412,
11018017, 17217616
+ BRAF:mut-NRAS + 19370421, 22613949, 19855393, 21779505,
16397024
er:FIGF + P–KDR_dimer:VEGFA + 18560389, 17933680, 20010945, 21248359,
21742222
MMP10 14967450, 16680569, 11349215, 11344033
Table 3
Ten signaling agents and their targets with a dissociation constant. The experimentally
measured dissociation constants of these signaling agents are mainly provided by the
study of Karaman and his colleagues [36].
Drug Target Dissociation constant (nM)
Dasatinib ABL1 0.53
EPHA3 0.09
EPHA5/8 0.24
PDGFRA 0.47
LYN 0.57
KIT 0.62
SRC 0.21
Erlotinib EGFR 0.67
ERBB4 230
LYN 530
SRC 700
Everolimus MTOR 2.2
Geﬁtinib EGFR 1.0
ERBB2 3500
ERBB4 410
LYN 990
Imatinib ABL1 12.0
ABL2 10.0
KIT 14.0
PDGFRA 31.0
PDGFRB 14.0
Lapatinib EGFR 2.4
ERBB2 7.0
ERBB4 54.0
Nilotinib KIT 22
PDGFRB 22
Sorafenib FLT3 13
FLT4 95
KIT 31
Sunitinib FLT3 0.47
KIT 0.37
PDGFRA 0.79
PDGFRB 0.08
Temsirolimus MTOR 2.2
VEGFR 0.75
Table 4
Drug response prediction of NCI-60 cancer cell lines with sensitivity and speciﬁcity. The
Cloppe–Pearson method was applied to calculate the 95% conﬁdence-interval (CI). The
deﬁnition of sensitivity and speciﬁcity is described in the Materials and methods.
Drug 95% Conﬁdence
interval
Sensitivity 95% Conﬁdence
interval
Speciﬁcity
Dasatinib [60.3, 92.0] 79.3% [29.1, 65.3] 46.9%
Erlotinib [23.2, 65.5] 43.5% [71.2, 95.6] 86.8%
Everolimus [75.7, 95.5] 88.0% [23.4, 83.3] 54.6%
Geﬁtinib [25.6, 67.2] 45.8% [74.6, 97.0] 89.2%
Imatinib [0.25, 44.5] 10.0% [89.6, 99.9] 98.0%
Lapatinib [34.5, 76.8] 56.5% [65.7, 92.3] 81.6%
Nilotinib [57.7, 91.4] 77.8% [43.6, 77.8] 61.8%
Sorafenib [85.8, 99.9] 97.3% [18.8, 59.4] 37.5%
Sunitinib [60.7, 88.9] 76.9% [59.7, 94.8] 81.8%
Temsirolimus [76.6, 95.7] 88.5% [29.9, 92.5] 66.7%
2839J. Li, U.R. Mansmann / Cellular Signalling 26 (2014) 2834–2842of oncomiRs such as mir-21, -155 and -210, were not reduced after ima-
tinib treatment. Therefore, this MSM based result proposes that an
increased signal ﬂux from these signaling pathways and certain
oncomiRs might contribute the non-response effect of NCI-60 cell
lines. In the MSM, the dasatinib inhibits the function of several key
proteins including the LYN, SRC, EPHAandKIT. Its sensitivity of response
prediction reaches a high speciﬁcity: 79.3% (95% CI [60.3; 92.0]),
however, its sensitivity is low: 46.9% (95% CI [29.1; 65.3]) (Table 4;
Supplementary information 4). The reason could be that inhibition of
these key targeted proteins directly leads to the suppression of the signal
ﬂux from other diverse signaling pathways such as the AKT-, MAPK-,
p38MAPK-, TP53-, and EGFR-signaling pathway. Formany types of can-
cer cell lines, the MSM could misunderstand that this type of inhibition
can reduce the proliferative rate and therefore predict them as
responders.
3. Conclusions
Cancer research over the past decades enriched the molecular
knowledge of detailed information of the signaling mechanism in can-
cer cells. To the present, many studies have been conducted to construct
signaling pathways by applying those molecular information. Most of
them focus on a single signaling pathway and cannot demonstrate the
potential for direct clinical applications [10,33,34]. However, the current
study collects different molecular information and applies them simul-
taneously to construct a genome-scale molecular signaling map
(MSM). The MSM incorporated several key cancer hallmarks proposed
by the study of Hanahan and Weinberg [14], which makes the ﬁrst
step in bringing mathematical implementation of the cancer hallmarktheory into practice. Via Petri net simulation, the MSM predicts the re-
sponses of NCI-60 cancer cell lines under ten signaling agents with
promising precision (in average, sensitivity: 76.9%; speciﬁcity: 62.6%).
The MSM based in silico prediction is only one speciﬁc use to quantify
the effects of molecular perturbation of signaling agents in cancer
cells. It is noteworthy that only the hallmark “proliferation” is used to
predict the drug response of cancer cell lines. Other hallmarks might
be useful regarding other aspects of cancer development. One of our on-
going studies is to apply the hallmark “drug resistance” to investigate
the skin rash effect of colon cancer patients with cetuximab treatment.
It is noteworthy that the implementation of cancer hallmarks repre-
sents only our current limited knowledge of cancer development and
empirical experience by molecular modeling. It is possible that these
implementation will be improved and revised extensively in future
studies.
Over the past two decades, a large number of drug discovery
programs were launched, which provides substantial evidence about
the clinical potential of the targeted therapy. Despite identiﬁcation of
relevant cancerous signaling pathways, there are still limited tools or
approaches that can facilitate prediction of response to targeted therapy
[35]. Because of this reason, the clinical usefulness and economical via-
bility of targeted therapy is mainly hampered. However, we think that
the MSM based in silico approach could be applied with modiﬁcation
to be directly combined with the targeted therapy to increase clinical
prediction and assessment and reduce clinical trial risk, although there
are still several limitations of the current approach. Firstly, it only
considers the drug inhibition effect regarding the dissociation constant
and ignores other factors including the pharmacokinetics and pharma-
codynamics of individual drugs,whichmight provide essential informa-
tion for prediction of drug effect. Secondly, the kinetic parameters used
in MSM Petri net simulation are mainly established based on empirical
experience. Lastly, although theMSMcontains a large amount ofmolec-
ular knowledge and information, a frequent update and improvement
of the MSM in the future is needed regarding the dramatic increase of
molecular knowledge. Despite the mentioned weaknesses of the cur-
rent approach, this study provides a proof-of-principle for exemplifying
the usefulness of this type of molecular signaling map.4. Materials and methods
4.1. The genomic data of NCI-60 cancer cell lines
The NCI-60 cancer cell lines are derived from 9 different types of
cancers: leukemia, non-small cell lung, colon, CNS, melanoma, ovarian,
renal, prostate, and breast. The gene expression data of these cancer
cell lines can be downloaded via the link in ref. [37]. The miRNA
expression data can be accessed via the link in ref. [38].
Fig. 4. Sensitivity scores of predicted responses of NCI-60 cancer cell lines towards sorafenib (A), temsirolimus (B), everolimus (C), and imatinib (D). The deﬁnition of sensitivity scores for
the experiment and simulation is described in the Materials and methods.
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2841J. Li, U.R. Mansmann / Cellular Signalling 26 (2014) 2834–28424.2. Modeling molecular inhibition of signaling agents
The chosen ten signaling agents aremainly competitive inhibitors of
receptor tyrosine kinase (RTKs) and have received regulatory approval
so far [39–46]. Their effect is to effectively and efﬁciently disrupt key
signaling pathways that tumors rely on for growth and survival [47].
The MSM modeling of the molecular inhibitions follow a generalized
modeling pattern (Fig. 1D). It reﬂects the complex-formation of a drug
and target-protein (drug:target) and its subsequent degradation. Each
modeled drug concentration in the MSM is deﬁned with regard to the
cancer cell lines, namely, it is set as the average gene expression level
of each corresponding cancer cell line. The functional target-protein
will be suppressed depending on the dissociation rate of individual
drugs. As a consequence, the signal ﬂux related to this target protein
will be reduced accordingly, which results in a change of the signal
ﬂux pattern into a perturbation state. Thereby, the FCA analysis is per-
formed to investigate whether the change of the signal ﬂux pattern
from a control state into a perturbation state could reduce the prolifer-
ation ability of a corresponding cancer cell line. The mathematical for-
mulation is:
drug : target½  ¼ drug½   target½ = 1þ dissociation constantð Þ
where [drug:target] denotes the concentration of the component drug:
target in themodel; drug:target denotes that the component is a complex
of the drug and target.
4.3. Algorithm of ﬂux-comparative-analysis (FCA) based on Petri net
The goal of the FCA analysis is to detect whether a therapeutic inter-
vention (drug treatment) can cause a signiﬁcant ﬂux change with re-
gard to the structure of an entire molecular network in order to
predict how an individual would respond to the therapeutic interven-
tion [13]. Essentially, during the FCA, two states are needed for each
cell line/patient for each treatment; one is the control state (without
treatment) and the other is the perturbation state (with treatment).
During the Petri net simulation, the ﬂux generated in themodel is com-
pared between both states for each cell line/patient. The following sim-
ulation algorithm code is applied to generate the ﬂux steady state of
each state:
1. Ri = the i-th reaction in the molecular model, and Ri possesses
items including speed (S), kinetic parameter (k), product (p),
reactant (a), enzyme (e)
2. Cj,t = the concentration of j-th bio-object (such as gene, protein) in
the model at the time step t
3. St = Ca,t ∗ Ce,t ∗ k
4. N, M = the amount of reactions and bio-objects in the model
respectively
5. For each j (from 1 to M) at the time step t:
6. if Cj,t− Cj,t − 5 N 0.001:
7. then reachSteadyState = False
8. If not reachSteadyState:
9. for each i (from 1 to N) at time step t:
10. if Cp,t − 1 b Ca,t − 1 & St b Ca,t − 1 ∗ 0.75:
11. then evaluate Ri for ﬁre at t:Table 5
Deﬁnition of true positive, true negative, false positive, and false negative. ESS: experimen-
tally measured sensitivity score from the study of Holbeck et al. [25]; PSS: MSM based pre-
dicted sensitivity score. Both types of sensitivity scores regarding these ten signaling agents
are visualized as scatter plots in the Supplementary information 4.
Prediction Condition
True positive ESS N 0; PSS N 0
True negative ESS ≤ 0; PSS ≤ 0
False positive ESS ≤ 0; PSS N 0
False negative ESS N 0; PSS ≤ 012. Cp,t = Cp,t − 1 + St
13. Ca,t = Ca.t − 1− St
14. If reachSteadyState:
15. select the readout components
The detailed description of FCA analysis is attached in Supplementary
information 3.
4.4. Deﬁnition of sensitivity score for drug response
1. Sensitivity score (experimental data) =MGI50 (MGI50: mean value of
GI50 of NCI-60 cancer cell lines; GI50: the logmol/L drug/concentration
yielding a growth inhibition of 50%) [25].
2. Sensitivity score (prediction data) = log(PD) (PD: relative change
value of readout component “proliferation” hallmark in the control
state compared to that in the tumor state. In this case, the hallmark
“proliferation” is selected as a readout component for the FCA
analysis).
It is noteworthy that the hallmark “proliferation” is the only applied
cancer hallmarks in the MSM for this type of prediction, because the
experimentally deﬁned sensitivity-score is based on the cellular growth,
which can be measured as the strengthening of proliferative ability.
4.5. Sensitivity and speciﬁcity
Sensitivity = number of true positives/total number of responded
cell lines; speciﬁcity = number of true negatives/total number of
non-responded cell lines. Table 5 shows four possibilities of prediction
performance. The experimentally measured sensitivity scores (ESS) by
the study of Holbeck et al. [25] are considered as real responses that
the NCI-60 cancer cell lines elicit during drug treatments. The exact
conﬁdence intervals [48] for rates have been performed to estimate
the probability of reached sensitivity and speciﬁcity of prediction of
each drug responses on NCI-60 cell lines.
4.6. Model availability
The MSMmodel is available under the URL found in ref. [49].
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